Search research articles
Contact Us
Filters
Showing results (711-720 of 732) with videos related to
Page
of 74
Sort By:
American Journal of Medical Genetics
|
February 25, 2000
Suggestive evidence of a locus on chromosome 10p using the NIMH genetics initiative bipolar affective disorder pedigrees
T Foroud, P F Castelluccio, D L Koller, et al.
Journal of Neurotrauma
|
September 23, 2017
The Biological Basis of Chronic Traumatic Encephalopathy following Blast Injury: A Literature Review
Matt Aldag, Regina C Armstrong, Faris Bandak, et al.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
JCO Precision Oncology
|
May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
Jacqueline A Shaw, Karen Page, Evie Wren, et al.
Molecular Oncology
|
December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
Andi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
ESMO Open
|
January 5, 2021
Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome
R J Lee, O Wysocki, T Bhogal, et al.
ESMO Open
|
February 5, 2021
Erratum to 'Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome': [ESMO Open Volume 6, Issue 1, February 2021, 100005]
R J Lee, O Wysocki, T Bhogal, et al.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Journal of Medicinal Chemistry
|
December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E
Martin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Nature
|
May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
Page
of 74
Search research articles
Search
Showing results (711-720 of 732) with videos related to
Sort By:
Page
of 74
American Journal of Medical Genetics
|
February 25, 2000
Suggestive evidence of a locus on chromosome 10p using the NIMH genetics initiative bipolar affective disorder pedigrees
T Foroud, P F Castelluccio, D L Koller, et al.
Journal of Neurotrauma
|
September 23, 2017
The Biological Basis of Chronic Traumatic Encephalopathy following Blast Injury: A Literature Review
Matt Aldag, Regina C Armstrong, Faris Bandak, et al.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
JCO Precision Oncology
|
May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
Jacqueline A Shaw, Karen Page, Evie Wren, et al.
Molecular Oncology
|
December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
Andi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
ESMO Open
|
January 5, 2021
Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome
R J Lee, O Wysocki, T Bhogal, et al.
ESMO Open
|
February 5, 2021
Erratum to 'Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome': [ESMO Open Volume 6, Issue 1, February 2021, 100005]
R J Lee, O Wysocki, T Bhogal, et al.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Journal of Medicinal Chemistry
|
December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E
Martin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Nature
|
May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
Page
of 74